Events Search and Views Navigation
May 2021
Currently the FDA categorizes psychedelics such as LSD and psilocybin as Schedule I drugs, indicating that these substances have no medical benefits. Despite this classification, a resurgence of research has demonstrated therapeutic benefits of psychedelics for treatment of psychiatric disorders. These exciting findings have resulted in a paradigm shift for treatment-resistant psychiatric conditions, along with [...]
Find out moreJune 2021
SLEEP 2021, the 35th annual meeting of the APSS, is a joint virtual meeting of the American Academy of Sleep Medicine and the Sleep Research Society. For more information, please visit https://www.sleepmeeting.org/. Dr. Maha Ahmad, Medical Director of the Sleep Disorders Institute & Clinilabs Drug Development Corporation will presenting. More details coming soon.
Find out moreSeptember 2021
Please join us this year and hear Dr. Zammit present followed by a live Q&A session after on September 8th, 2021. More details to come. The scarcity of new drugs for neuropsychiatric disorders contrasts with the extraordinary advances in neuroscience research to date. Focusing from bench to bedside, and built with thought-leaders at Sage Therapeutics, [...]
Find out moreNovember 2021
Join the pharma and biotech R&D leaders, the top tech companies involved in clinical development and healthcare innovation, investigator sites, service companies, and the regulators from FDA and EMA at CNS Summit 2021. Experience a dynamic environment for networking and idea sharing, for learning from industry leaders and exploring the future of drug development. You’ll [...]
Find out moreAt each OCT, we look forward to an educational program packed with the latest case studies, techniques, and providers to set your trial apart. 2021 will be no different and the Arena team will bring some of the leading voices in clinical outsourcing who are best situated to answer your questions and provide you the [...]
Find out more